Format

Send to

Choose Destination
Biochem Biophys Res Commun. 2018 Nov 17;506(1):266-271. doi: 10.1016/j.bbrc.2018.10.089. Epub 2018 Oct 19.

Depletion of SIRT7 sensitizes human non-small cell lung cancer cells to gemcitabine therapy by inhibiting autophagy.

Author information

1
The Third Affiliated Hospital of Qiqihar Medical University, 161000, China.
2
The Third Affiliated Hospital of Qiqihar Medical University, 161000, China. Electronic address: wbhao2017@126.com.

Abstract

Anti-metabolic therapy, as a major chemotherapy, is an important option in the treatment of lung cancer. However, tumor resistance to cytotoxic chemotherapy has become more common. It has been reported that autophagy is one of the processes contributing to such resistance. In our study, we find that SIRT7 protein level elevated dramatically in response to an anti-metabolic drug-gemcitabine treatment. Moreover, autophagy induced by gemcitabine in non-small cell lung cancer cells is SIRT7-dependent. Furthermore, depletion of SIRT7 promoted Gemcitabine-induced cell death. Our report also shows that SIRT7 knockdown markedly improves the anti-tumor activity of gemcitabine treatment in mice. These results suggest that SIRT7-elicits an autophagic response that plays a protective role against cell death and the SIRT7-inhibition has a potential to improve the efficacy of anti-metabolic therapy in non-small cell lung cancer cells.

KEYWORDS:

Autophagy; Gemcitabine therapy; Non-small cell lung cancer (NSCLC); SIRT7

PMID:
30348528
DOI:
10.1016/j.bbrc.2018.10.089
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center